38 results on '"OVERALL survival"'
Search Results
2. Impactful Studies Challenge the Status Quo at GI Conference.
3. Novel Approaches Focus on Limiting Toxicity in Older Patients with ALL.
4. Expanding 177Lutetium-PSMA-617 Use in the Community.
5. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.
6. Clinical Updates: BLADDER CANCER. Adding durvalumab to chemotherapy extends survival in MIBC.
7. Blue light cystoscopy decreases risk of recurrence, progression in NMIBC.
8. Paclitaxel/Ramucirumab Prolongs Survival in Gastric Cancer.
9. Perioperative Chemotherapy With FLOT Improves OS in Resectable Esophageal Cancer.
10. Unlocking Latest Insights Into HR-Positive, HER2-Negative Treatment Strategies.
11. Nogapendekin alfa inbakicept-pmln (N-803; Anktiva).
12. Linvoseltamab Delivers Deep, Durable Responses in R/R Multiple Myeloma.
13. Amivantamab/Chemotherapy Prolongs Progression-Free Survival in NSCLC.
14. FDA Committee Agrees That MRD Is a Viable End Point in Myeloma Trials.
15. FDA Grants Full Approval to Elahere.
16. Pembrolizumab Combination Shows Positive OS Trend in Endometrial Cancer.
17. First-Line Durvalumab Improves PFS in Advanced Endometrial Cancer.
18. Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC.
19. Addressing irAEs Limits Interruption or Discontinuation in HCC.
20. Acalabrutinib With Axi-Cel Reveals Promising Responses in R/R B-Cell Lymphoma.
21. Survival Benefits Displayed After Stem Cell Transplant With Orca-T vs PTCy.
22. Amivantamab-vmjw (Rybrevant).
23. Ibrutinib, Venetoclax Trial Boosts PFS in MCL.
24. Trastuzumab Deruxtecan (T-Dxd; Enhertu).
25. FDA Sets Date for First-in-Class Lung Cancer Therapy.
26. FDA Approves Onivyde for First-line Metastatic Pancreatic Cancer.
27. FDA Sets Advisory Meeting for Abecma in Supplemental Multiple Myeloma Indication.
28. Exploring the Financial Advantages of Adding a CDK 4/6 Inhibitor to ER-Positive Breast Cancer.
29. CAPTURE Trial Reveals BRCA Mutations Are Linked to Worse Outcomes in mCRPC.
30. Alectinib (Alecensa).
31. Orca-T Use Demonstrates Promise for Patients With Hematologic Malignant Tumors.
32. What Is High-Risk Mantle Cell Lymphoma, and How Should We Treat It?
33. Ribociclib Combo Delivers OS, PFS Benefits in HR-Positive Breast Cancer.
34. Mirvetuximab Soravtansine-gynx (Elahere): DECEMBER 5, 2023.
35. Lenvatinib Is Effective, Regardless of Age in HCC.
36. Nivolumab (Opdivo).
37. Ponatinib (Iclusig).
38. Enhanced Effectiveness Is Noted in Nivolumab Combo for Advanced GI Cancers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.